Deal with Zoetis could be worth $500 mn in 10 yrs: Syngene In'l chief

In a Q&A, Jonathan Hunt, MD & CEO of the Biocon arm, dwells on his firm's initiatives to overcome supply chain bottlenecks and other issues

Biocon arm SyngeneInternational has signed a 10-year agreement to manufacture the drug substance for Librela, a monoclonal antibody used to treat osteoarthritis in dogs,along with the development and manufacturing of other molecules,with US-based animal health company Zoetis. Syngeneis expanding its capacities and expects to tap more opportunities in this space. Managing Director and Chief ExecutiveOfficer, SyngeneInternational, Jonathan Hunt speaks to Sohini Das on the road ahead. Edited excerpts.

Is there a possibility to scale up this manufacturing contract with Zoetis?

We have had a long relationship with Zoetis of over a decade. It started out on the research discovery side